Habitual glucosamine use, APOE genotypes, and risk of incident cause-specific dementia in the older population.
APOE genotypes
Alzheimer’s disease
Glucosamine supplement
Vascular dementia
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
09 09 2023
09 09 2023
Historique:
received:
03
01
2023
accepted:
24
08
2023
medline:
11
9
2023
pubmed:
10
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
The relationship of glucosamine use with incident dementia in the older population remains uncertain. We aimed to evaluate the longitudinal association between habitual glucosamine supplement and the risk of cause-specific dementia and examine the possible effect modifiers on this association. The study included 214,945 participants over the age of 60 who had available information on glucosamine use and did not have dementia at baseline in the UK Biobank. The APOE genotypes were determined by a combination variant of rs429358 and rs7412. The primary outcome was incident vascular dementia, incident Alzheimer's disease, and incident frontotemporal dementia, respectively. Over a median follow-up duration of 12 years, 1039, 1774, and 122 participants developed vascular dementia, Alzheimer's disease, and frontotemporal dementia, respectively. Overall, habitual glucosamine use was significantly associated with a lower risk of incident vascular dementia (adjusted HR, 0.82; 95%CI, 0.70-0.96), but not significantly associated with incident Alzheimer's disease (adjusted HR, 1.02; 95%CI, 0.92-1.14) and incident frontotemporal dementia (adjusted HR, 0.95; 95%CI, 0.63-1.43). Moreover, the inverse association between habitual glucosamine use and incident vascular dementia was more pronounced in participants with concomitant supplement of calcium (P-interaction = 0.011), and those without concomitant supplement of zinc (P-interaction = 0.018). However, APOE ε4 dosage and baseline cognitive function did not significantly modify the relationships of glucosamine use with incident vascular dementia or Alzheimer's disease (All P-interactions > 0.05). Regardless of APOE genotypes and baseline cognitive function, habitual glucosamine use was significantly inversely associated with incident vascular dementia in the older population.
Sections du résumé
BACKGROUND
The relationship of glucosamine use with incident dementia in the older population remains uncertain. We aimed to evaluate the longitudinal association between habitual glucosamine supplement and the risk of cause-specific dementia and examine the possible effect modifiers on this association.
METHODS
The study included 214,945 participants over the age of 60 who had available information on glucosamine use and did not have dementia at baseline in the UK Biobank. The APOE genotypes were determined by a combination variant of rs429358 and rs7412. The primary outcome was incident vascular dementia, incident Alzheimer's disease, and incident frontotemporal dementia, respectively.
RESULTS
Over a median follow-up duration of 12 years, 1039, 1774, and 122 participants developed vascular dementia, Alzheimer's disease, and frontotemporal dementia, respectively. Overall, habitual glucosamine use was significantly associated with a lower risk of incident vascular dementia (adjusted HR, 0.82; 95%CI, 0.70-0.96), but not significantly associated with incident Alzheimer's disease (adjusted HR, 1.02; 95%CI, 0.92-1.14) and incident frontotemporal dementia (adjusted HR, 0.95; 95%CI, 0.63-1.43). Moreover, the inverse association between habitual glucosamine use and incident vascular dementia was more pronounced in participants with concomitant supplement of calcium (P-interaction = 0.011), and those without concomitant supplement of zinc (P-interaction = 0.018). However, APOE ε4 dosage and baseline cognitive function did not significantly modify the relationships of glucosamine use with incident vascular dementia or Alzheimer's disease (All P-interactions > 0.05).
CONCLUSIONS
Regardless of APOE genotypes and baseline cognitive function, habitual glucosamine use was significantly inversely associated with incident vascular dementia in the older population.
Identifiants
pubmed: 37689747
doi: 10.1186/s13195-023-01295-6
pii: 10.1186/s13195-023-01295-6
pmc: PMC10492372
doi:
Substances chimiques
Glucosamine
N08U5BOQ1K
Apolipoproteins E
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
152Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Ann Rheum Dis. 2016 Jan;75(1):37-44
pubmed: 25589511
Neuropharmacology. 2018 May 15;134(Pt B):226-239
pubmed: 29273521
Int J Epidemiol. 2023 Oct 5;52(5):1592-1611
pubmed: 36749099
J Proteome Res. 2006 Jan;5(1):196-201
pubmed: 16396512
Eur J Epidemiol. 2019 Jun;34(6):557-565
pubmed: 30806901
J Alzheimers Dis. 2020;76(2):713-724
pubmed: 32538835
Age Ageing. 2016 Jul;45(4):511-7
pubmed: 27103599
Alzheimers Dement. 2021 Sep;17(9):1422-1431
pubmed: 33749976
Drugs. 2020 Dec;80(18):1947-1959
pubmed: 33074440
Cartilage. 2016 Jan;7(1):70-81
pubmed: 26958319
BMJ Open. 2016 Nov 30;6(11):e012177
pubmed: 27903560
Inflammopharmacology. 2013 Feb;21(1):79-90
pubmed: 22821424
Int Rev Cell Mol Biol. 2016;326:201-78
pubmed: 27572130
Mol Neurobiol. 2018 Nov;55(11):8738-8753
pubmed: 29589284
N Engl J Med. 2006 Feb 23;354(8):795-808
pubmed: 16495392
Nature. 2006 Dec 14;444(7121):860-7
pubmed: 17167474
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Am J Epidemiol. 2012 Dec 1;176(11):1002-13
pubmed: 23139249
BMJ. 2019 May 14;365:l1628
pubmed: 31088786
Adv Nutr. 2021 Feb 1;12(1):141-160
pubmed: 32722790
Neuromolecular Med. 2022 Jun;24(2):125-138
pubmed: 34117614
Acta Psychiatr Scand. 2017 Jun;135(6):593-605
pubmed: 28387438
Alzheimer Dis Assoc Disord. 2014 Jul-Sep;28(3):206-18
pubmed: 24632990
Alzheimers Dement. 2018 Aug;14(8):1038-1051
pubmed: 29621480
Semin Arthritis Rheum. 2021 Feb;51(1):292-298
pubmed: 33433365
J Gerontol A Biol Sci Med Sci. 2023 May 09;:
pubmed: 37158699
Molecules. 2020 Aug 12;25(16):
pubmed: 32806562
Ageing Res Rev. 2019 Nov;55:100944
pubmed: 31430566
Cell Host Microbe. 2020 Aug 12;28(2):201-222
pubmed: 32791113
Alzheimers Dement. 2018 Jul;14(7):895-901
pubmed: 29548722
Nat Sci Sleep. 2022 Feb 09;14:181-191
pubmed: 35173500
Circulation. 2010 Feb 2;121(4):586-613
pubmed: 20089546
PLoS One. 2020 Apr 20;15(4):e0231627
pubmed: 32310977
Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H268-76
pubmed: 19411287
Osteoarthritis Cartilage. 2003 Apr;11(4):290-8
pubmed: 12681956
Arthritis Rheumatol. 2017 Jan;69(1):77-85
pubmed: 27477804
Am J Epidemiol. 2017 Nov 1;186(9):1026-1034
pubmed: 28641372
Circulation. 2006 Jul 4;114(1):82-96
pubmed: 16785338
Ann Rheum Dis. 2017 Nov;76(11):1862-1869
pubmed: 28754801
Natl Health Stat Report. 2008 Dec 10;(12):1-23
pubmed: 19361005
J Alzheimers Dis. 2019;72(4):1145-1157
pubmed: 31683474
Mol Psychiatry. 2014 Jan;19(1):76-87
pubmed: 23207651
Nat Genet. 2019 Mar;51(3):414-430
pubmed: 30820047
BMC Med. 2023 Mar 29;21(1):114
pubmed: 36978077
Neurology. 2016 Oct 18;87(16):1674-1680
pubmed: 27534711
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
PLoS One. 2012;7(7):e41540
pubmed: 22859995
Diabetes Care. 2020 Apr;43(4):719-725
pubmed: 31988063